智通财经APP获悉，银诺医药-B(02591)回吐逾13%，此前两周股价累计涨幅达50%。截至发稿，跌 13.64%，报38港元，成交额3031.07万港元。 消息面上，上交所、深交所发布公告称，因恒生综合中型股指数实施成份股调整，根据有关规定，港股 通标的名单发生调整，将银诺医药调入港股通，自2025年12月8日起生效。此外，银诺医药宣布，公司 自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α（怡诺轻®）正式纳入2025年国家医保药品目录， 将自2026年1月1日起与新版目录同步实施。 ...

Core Points - The Shenzhen Stock Exchange announced on December 8 that due to the adjustment of the Hang Seng Composite Midcap Index, the list of eligible securities for the Hong Kong Stock Connect will be updated, effective from December 8, 2025 [1] Group 1: Company Adjustments - Four companies have been added to the Hong Kong Stock Connect: FWD Group (01828), Aux Group (02580), Sinopharm Group (02591), and Chery Automobile (09973) [1][3] - The adjustment reflects the ongoing changes in the market and the inclusion of mid-cap stocks in the investment framework [1]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

银诺医药-B(02591)发布公告，集团核心产品(即依苏帕格鲁肽α)已成功纳入中国最新版《国家医保药品 目录》(2025年版)，用于治疗2型糖尿病("T2D")适应症。最新版《国家医保药品目录》将于2026年1月1 日正式生效。 ...

依苏帕格鲁肽α是集团研发的国内首款原研人源长效GLP-1受体激动剂，并于今年1月在中国获批用于单 药治疗及联合二甲双胍治疗T2D。依苏帕格鲁肽α用于治疗T2D和其他代谢性疾病。依苏帕格鲁肽α的临 床研究证明其起效快、疗效强且持久、半衰期长及安全性良好。 格隆汇12月7日丨银诺医药-B(02591.HK)公告，集团核心产品(即依苏帕格鲁肽α)已成功纳入中国最新版 《国家医保药品目录》(2025年版)("《国家医保药品目录》")，用于治疗2型糖尿病("T2D")适应症。最新 版《国家医保药品目录》将于2026年1月1日正式生效。 依苏帕格鲁肽α起效快、疗效强且持久。在III期临床试验中，经过前4周的治疗，接受依苏帕格鲁肽α单 药治疗(3.0mg)的T2D患者的糖化血红蛋白(HbA1c)水平降低了1.1%。依苏帕格鲁肽α亦展现出卓越的降 糖效果。在一项随机双盲安慰剂对照III期临床试验中，1.0mg和3.0mg剂量的依苏帕格鲁肽α单药治疗在 第24周时使HbA1c分别较基线显著降低1.7%和2.2%，具有统计学和临床意义。 依苏帕格鲁肽α表现出长达204小时的平均半衰期。依苏帕格鲁肽α延长的长效作用能够在长期疾病管 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」）作出，以向本公司股東 （「股東」）及有意投資者告知有關本公司近期的業務發展。 自願性公告 本公司核心產品納入《國家醫保藥品目錄》 － 依蘇帕格魯肽α安全性良好。在依蘇帕格魯肽α的臨床試驗中，均未觀察到藥 物相關2級或以上低血糖症案例。 有關本集團核心產品（即依蘇帕格魯肽α）的進一步詳情，請參閱本公司日期為 2025年8月7日的招股章程。 承董事會命 廣州銀諾醫藥集團股份有限公司 董事長 WANG QINGHUA博士 中華人民共和國，上海，2025年12月7日 董事會欣然宣佈，本集團核心產品（即依蘇帕格魯肽α）已成功納入中國最新版 《國家醫保藥品目錄》（2025年版） ...

银诺医药-B(02591)再涨超5%，股价暂现三连阳。截至发稿，涨5.03%，报43.42港元，成交额764.33万 港元。 消息面上，恒生指数系列季度检讨结果此前公布，其中，银诺医药获纳入恒生综合指数成份股，变动将 于2025年12月8日起生效。据中金预测，银诺医药等符合港股通纳入范围。公开资料显示，银诺医药是 一家专注于代谢性疾病领域的生物医药公司，目前拥有多项针对糖尿病、肥胖和非酒精性脂肪性肝炎等 适应症的创新药物研发管线，全部为自主研发，具备全球知识产权，覆盖全球研发与市场布局。 ...

智通财经APP获悉，银诺医药-B(02591)再涨超5%，股价暂现三连阳。截至发稿，涨5.03%，报43.42港 元，成交额764.33万港元。 消息面上，恒生指数系列季度检讨结果此前公布，其中，银诺医药获纳入恒生综合指数成份股，变动将 于2025年12月8日起生效。据中金预测，银诺医药等符合港股通纳入范围。公开资料显示，银诺医药是 一家专注于代谢性疾病领域的生物医药公司，目前拥有多项针对糖尿病、肥胖和非酒精性脂肪性肝炎等 适应症的创新药物研发管线，全部为自主研发，具备全球知识产权，覆盖全球研发与市场布局。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | ...

银诺医药-B(02591)公布，于2025年12月1日，公司及银诺技术(公司一间直接全资附属公司)以代价合共 人民币1.25亿元(即其总本金额)分别向宁波银行认购一款结构性存款产品(即宁波银行结构性存款产 品)。 ...